# Alcestobart

Source: https://onco.cc/drugs/alcestobart/  
OnCo record `alcestobart` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Alcestobart is an experimental monoclonal antibody from Nanjing Leads Biolabs, in phase 2 trials for nasopharyngeal carcinoma and melanoma.

## Summary

Alcestobart (LBL-007) is a monoclonal antibody (fully human IgG4) from Nanjing Leads Biolabs. A fully human IgG4 antibody against LAG-3 that blocks LAG-3 binding to its inhibitory ligands and causes LAG-3 to be taken into the cell, reducing it on the cell surface. Its furthest stage is phase 2, for nasopharyngeal carcinoma and melanoma. ClinicalTrials.gov registers it in 9 studies linked below. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: LBL-007
- Tags: pipeline; ctgov-ingest
- Code: LBL-007
- Modality: Monoclonal antibody (fully human IgG4)
- Mechanism: A fully human IgG4 antibody against LAG-3 that blocks LAG-3 binding to its inhibitory ligands and causes LAG-3 to be taken into the cell, reducing it on the cell surface.

## Sources

- Nanjing Leads Biolabs: leadsbiolabs.com: https://www.leadsbiolabs.com/_nuxt/C0xAGIJr.js
- Nanjing Leads Biolabs: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT05609370
- ClinicalTrials.gov: trials of LBL-007: https://clinicaltrials.gov/search?intr=LBL-007

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- targets: [LAG-3](https://onco.cc/targets/lag3/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)
- trials: [A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors](https://onco.cc/trials/nct05102006/), [A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors](https://onco.cc/trials/nct05516914/), [A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus ](https://onco.cc/trials/nct05609370/), [A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma](https://onco.cc/trials/nct05909904/), [A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05635708/), [A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma](https://onco.cc/trials/nct04640545/), [A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma](https://onco.cc/trials/nct06010303/), [Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05577702/), [Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors](https://onco.cc/trials/nct03744468/)

---
JSON: https://onco.cc/api/v1/entities/alcestobart.json